DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Ryan White HIV/AIDS Program Parts A and B Integrated HIV Planning Implementation Cooperative Agreement to John Snow, Inc. (JSI), U69HA30144

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of non-competitive FY 2018 supplemental award.

SUMMARY: This noncompetitive supplement award to JSI will support and strengthen current Ryan White HIV/AIDS Program (RWHAP) Part A and Part B priority setting and resource allocation processes to ensure people living with HIV are linked to care, remain engaged in care, and achieve viral suppression.

FOR FURTHER INFORMATION CONTACT: Dr. Rene Sterling, Acting Director, Division of State HIV/AIDS Programs, HIV/AIDS Bureau, HRSA; 5600 Fishers Lane, Room 00W50, Rockville, MD 20857; Phone: (301) 443–9017; Email: rsterling@hrsa.gov.

SUPPLEMENTARY INFORMATION: Intended Recipient of the Award: JSI (U69HA30144).

Amount of Non-Competitive Award: $300,000 in FY 2018.

Period of Funding: July 1, 2018, through June 30, 2019.

CFDA Number: No. 93.145.

Authority: Sections 2606 and 2654(b) of the Public Health Service Act, as amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87).

Justification: In 2016, JSI was awarded a 3-year cooperative agreement under HRSA–16–082 RWHAP Integrated HIV Planning Implementation (CFDA 93.145), authorized by Sections 2606 and 2654(b) of the Public Health Service Act, as amended by the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Pub. L. 111–87). The cooperative agreement was established to provide technical assistance to RWHAP Parts A and B recipients and their planning bodies regarding: (1) The integration of HIV planning across prevention, care, and treatment service delivery systems; and (2) the development, implementation, monitoring, and evaluation of Integrated HIV Prevention and Care Plans. RWHAP Parts A and B recipients and planning bodies use Integrated Plans to better inform and coordinate HIV prevention and care program planning, resource allocation, and continuous quality improvement efforts to meet the HIV service delivery needs within their jurisdictions.

The proposed supplemental funding will provide RWHAP Parts A and B recipients with additional technical assistance (TA) specifically focused on resource allocation planning and implementation. These additional TA activities will build upon data elements identified in the Integrated Plan and provide jurisdictions with strategies, tools, and resources to effectively allocate annual available resources to prioritize HIV unmet needs. The TA activities will be directed at addressing more efficient and proactive methods in the Priority Setting and Resource Allocation (PSRA) process to increase the ability of health care providers and systems to ensure people living with HIV are linked to care, remain engaged in care, and achieve HIV viral suppression.

Dated: June 12, 2018.

George Sigounas,
Administrator.

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

TABLE 1—LIST OF INFORMATION COLLECTIONS APPROVED BY OMB

<table>
<thead>
<tr>
<th>Title of collection</th>
<th>OMB control No.</th>
<th>Date approval expires</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infant Formula Requirements</td>
<td>0910–0256</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Premarket Notification for a New Dietary Ingredient</td>
<td>0910–0330</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Regulations for In Vivo Radiopharmaceuticals Used for Diagnosis and Monitoring</td>
<td>0910–0409</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Requests for Inspection by an Accredited Person Under the Inspection for Accredited Persons Program</td>
<td>0910–0569</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Substances Prohibited from Use in Animal Food or Feed</td>
<td>0910–0627</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Guidance for Industry: Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic</td>
<td>0910–0701</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Human Subject Protection; Acceptance of Data From Clinical Investigations for Medical Devices</td>
<td>0910–0741</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Food Labeling; Calorie Labeling of Articles of Food in Vending Machines and Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments</td>
<td>0910–0782</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings with the Office of Orphan Products Development</td>
<td>0910–0787</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Food Allergen Labeling and Reporting</td>
<td>0910–0792</td>
<td>5/31/2021</td>
</tr>
<tr>
<td>Transfer of a Premarket Notification Clearance</td>
<td>0910–0852</td>
<td>5/31/2021</td>
</tr>
</tbody>
</table>
would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Immunity in the Elderly (R01)

**Date:** July 9–10, 2018.

**Time:** 9:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health LD30, 5601 Fishers Lane, Rockville, MD 20892.

**Contact Person:** Julio Aliberti, Ph.D., Scientific Review Officer, Scientific Review Program, DE/AID/NIAID/NIH/DHHS, 5601 Fishers Lane, MSC–9823, Rockville, MD 20852, 301–761–7322, alibertiai@niaid.nih.gov.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Maintaining Immunity after Allergy and Infectious Diseases Special Emphasis Panel; NIAID INVESTIGATOR INITIATED PROGRAM PROJECT (P01).

**Date:** July 11–12, 2018.

**Time:** 8:30 a.m. to 2:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892.

**Contact Person:** Geetanjali Bansal, Ph.D., Scientific Reviewer Officer, Scientific Review Program, Division of Extramural Activities, Room 3C49, National Institutes of Health/ NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892–9834, (240) 669–5073, geetanjali.bansal@nih.gov.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID INVESTIGATOR INITIATED PROGRAM PROJECT (P01).

**Date:** July 11, 2018.

**Time:** 1:00 p.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892, (Telephone Conference Call).

**Contact Person:** Raymond R. Schleef, Ph.D., Senior Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E01, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5019, schleefrr@nih.gov.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID INVESTIGATOR INITIATED PROGRAM PROJECT (P01).

**Date:** June 13, 2018.

**Natasha M. Copeland,** Program Analyst, Office of Federal Advisory Committee Policy.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Substance Abuse and Mental Health Services Administration**

**Notice of Meeting**

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Substance Abuse Prevention’s (CSAP) Drug Testing Advisory Board (DTAB) will convene via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT.

The board will meet in closed-session via web conference on August 8, 2018, from 9:00 a.m. EDT to 5:00 p.m. EDT to discuss the proposed Mandatory Guidelines for Federal Workplace Drug Testing Programs (hair specimens). Therefore, the meeting is closed to the public as determined by the Assistant Secretary for Mental Health and Substance Use, SAMHSA, in accordance with 5 U.S.C. 552b(c)(4) and (9)(B), and 5 U.S.C. App. 2, Section 10(d).

Meeting registration information can be completed at http://snacregister.samhsa.gov/MeetingList.aspx. Web conference and call information will be sent after completing registration. Meeting information and a roster of DTAB members may be obtained by accessing the SAMHSA Advisory Committees website, http://www.samhsa.gov/about-us/advisory-councils/drug-testing-advisory-board-dtab or by contacting the Designated Federal Officer, CAPT Sean J. Belouin, USPHS.

**Committee Name:** Substance Abuse and Mental Health Services Administration’s Drug Testing Advisory Board.

**Dates/Time/Type:** August 8, 2018, from 9:00 a.m. to 5:00 p.m. EDT: CLOSED.

**Place:** Web Conference.

**Contact:** CAPT Sean J. Belouin, USPHS, Senior Pharmacology and Regulatory Policy Advisor, Division of Workplace Programs, 5600 Fishers Lane, Room 16N06D, Rockville, Maryland 20857; Telephone: (240) 276–2600, Email: sean.belouin@samhsa.hhs.gov.

**Carlos Castillo,** Committee Management Officer, SAMHSA.

**DEPARTMENT OF HOMELAND SECURITY**

**Federal Emergency Management Agency**

**[Docket ID FEMA–2018–0002; Internal Agency Docket No. FEMA–B–1830]**

**Proposed Flood Hazard Determinations**

**AGENCY:** Federal Emergency Management Agency, DHS.

**ACTION:** Notice.

**SUMMARY:** Comments are requested on proposed flood hazard determinations, which may include additions or modifications of any Base Flood Elevation (BFE), base flood depth, Special Flood Hazard Area (SFHA) boundary or zone designation, or regulatory floodway on the Flood Insurance Rate Maps (FIRMs), and where applicable, in the supporting Flood Insurance Study (FIS) reports for the communities listed in the table below. The purpose of this notice is to seek general information and comment regarding the preliminary FIRM, and where applicable, the FIS report that the Federal Emergency Management Agency (FEMA) has provided to the affected communities. The FIRM and FIS report are the basis of the floodplain management measures that the community is required either to adopt or to show evidence of having in effect in order to qualify or remain qualified for participation in the National Flood Insurance Program (NFIP). In addition, the FIRM and FIS report, once effective, will be used by insurance agents and others to calculate appropriate flood insurance premium rates for new buildings and the contents of those buildings.

**DATES:** Comments are to be submitted on or before September 17, 2018.

**ADDRESSES:** The Preliminary FIRM, and where applicable, the FIS report for each community are available for inspection at both the online location https://www.fema.gov/preliminaryfloodhazarddata and the respective Community Map Repository address listed in the tables below. Additionally, the current effective FIRM and FIS report for each community are accessible online through the FEMA Map Service Center at https://msc.fema.gov for comparison.

You may submit comments, identified by Docket No. FEMA–B–1830, to Rick Sachibit, Chief, Engineering Services Branch, Federal Insurance and Mitigation Administration, FEMA, 400 C Street SW, Washington, DC 20472,